Switch theme
Sign up to access all valuation multiples
Bavarian Nordic AS is a biotechnology company focused on the research, development, manufacturing, and commercialization of life-saving vaccines. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets. Its products include Encepur, Jynneos, Rabipur, Vaxchora and Vivotif.
1994
1.7K+
LTM Revenue $899M
LTM EBITDA $263M
$1.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Bavarian Nordic has a last 12-month revenue (LTM) of $899M and a last 12-month EBITDA of $263M.
In the most recent fiscal year, Bavarian Nordic achieved revenue of $861M and an EBITDA of $252M.
Bavarian Nordic expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Bavarian Nordic valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $899M | XXX | $861M | XXX | XXX | XXX |
| Gross Profit | $454M | XXX | $425M | XXX | XXX | XXX |
| Gross Margin | 51% | XXX | 49% | XXX | XXX | XXX |
| EBITDA | $263M | XXX | $252M | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 29% | XXX | XXX | XXX |
| EBIT | $170M | XXX | $142M | XXX | XXX | XXX |
| EBIT Margin | 19% | XXX | 16% | XXX | XXX | XXX |
| Net Profit | $153M | XXX | $149M | XXX | XXX | XXX |
| Net Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Bavarian Nordic's stock price is DKK 173 (or $26).
Bavarian Nordic has current market cap of DKK 13.5B (or $2.0B), and EV of DKK 12.3B (or $1.9B).
See Bavarian Nordic trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.9B | $2.0B | XXX | XXX | XXX | XXX | $2.04 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Bavarian Nordic has market cap of $2.0B and EV of $1.9B.
Bavarian Nordic's trades at 2.2x EV/Revenue multiple, and 7.4x EV/EBITDA.
Equity research analysts estimate Bavarian Nordic's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bavarian Nordic has a P/E ratio of 13.2x.
See valuation multiples for Bavarian Nordic and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.0B | XXX | $2.0B | XXX | XXX | XXX |
| EV (current) | $1.9B | XXX | $1.9B | XXX | XXX | XXX |
| EV/Revenue | 2.1x | XXX | 2.2x | XXX | XXX | XXX |
| EV/EBITDA | 7.1x | XXX | 7.4x | XXX | XXX | XXX |
| EV/EBIT | 10.9x | XXX | 13.1x | XXX | XXX | XXX |
| EV/Gross Profit | 4.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 13.2x | XXX | 13.6x | XXX | XXX | XXX |
| EV/FCF | 19.5x | XXX | 47.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBavarian Nordic's last 12 month revenue growth is 1%
Bavarian Nordic's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Bavarian Nordic's rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bavarian Nordic's rule of X is 33% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Bavarian Nordic and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1% | XXX | -1% | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | -3% | XXX | XXX | XXX |
| Rule of 40 | 32% | XXX | 31% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 33% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 9% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 15% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 33% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bavarian Nordic acquired XXX companies to date.
Last acquisition by Bavarian Nordic was XXXXXXXX, XXXXX XXXXX XXXXXX . Bavarian Nordic acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Bavarian Nordic founded? | Bavarian Nordic was founded in 1994. |
| Where is Bavarian Nordic headquartered? | Bavarian Nordic is headquartered in Denmark. |
| How many employees does Bavarian Nordic have? | As of today, Bavarian Nordic has 1.7K+ employees. |
| Who is the CEO of Bavarian Nordic? | Bavarian Nordic's CEO is Mr. Paul Chaplin. |
| Is Bavarian Nordic publicy listed? | Yes, Bavarian Nordic is a public company listed on CSE. |
| What is the stock symbol of Bavarian Nordic? | Bavarian Nordic trades under BAVA ticker. |
| When did Bavarian Nordic go public? | Bavarian Nordic went public in 1998. |
| Who are competitors of Bavarian Nordic? | Similar companies to Bavarian Nordic include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of Bavarian Nordic? | Bavarian Nordic's current market cap is $2.0B |
| What is the current revenue of Bavarian Nordic? | Bavarian Nordic's last 12 months revenue is $899M. |
| What is the current revenue growth of Bavarian Nordic? | Bavarian Nordic revenue growth (NTM/LTM) is 1%. |
| What is the current EV/Revenue multiple of Bavarian Nordic? | Current revenue multiple of Bavarian Nordic is 2.1x. |
| Is Bavarian Nordic profitable? | Yes, Bavarian Nordic is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Bavarian Nordic? | Bavarian Nordic's last 12 months EBITDA is $263M. |
| What is Bavarian Nordic's EBITDA margin? | Bavarian Nordic's last 12 months EBITDA margin is 29%. |
| What is the current EV/EBITDA multiple of Bavarian Nordic? | Current EBITDA multiple of Bavarian Nordic is 7.1x. |
| What is the current FCF of Bavarian Nordic? | Bavarian Nordic's last 12 months FCF is $95.2M. |
| What is Bavarian Nordic's FCF margin? | Bavarian Nordic's last 12 months FCF margin is 11%. |
| What is the current EV/FCF multiple of Bavarian Nordic? | Current FCF multiple of Bavarian Nordic is 19.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
